Topics:
Gynecologic Cancers • Medical Oncology • Immune-related adverse events • Rheumatology • General Rheumatology
When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?
How do you decide if it may be safe to continue immunotherapy?
Answer from: at Academic Institution
If the symptoms/signs are similar to their prior flares of their rheumatic disease, then it is likely a flare. Over 50% of patients with autoimmune diseases flare on immune checkpoint inhibitor therapy if you look at systematic literature reviews of the limited published data.
If symptoms are unrel...
Sign in or Register to read more